ReviewInnovation (Cambridge (Mass.))2026
Unlocking new frontiers in bioimaging: The power of FLIM-AIE integration.
Review in Innovation (Cambridge (Mass.)), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The frontiers of bioimaging encompass cutting-edge technologies and methodologies that enhance the visualization, analysis, and interpretation of biological structures and processes with unprecedented precision. In this context, fluorescence lifetime imaging microscopy (FLIM) has emerged as a powerful technique that enables quantitative and concentration-independent imaging by measuring the fluorescence decay time of molecular probes. Unlike intensity-based fluorescence methods, FLIM provides robust data on molecular interactions, environments, and biomarker presence, making it invaluable for bioimaging. However, its widespread adoption remains constrained by technical complexity, the high cost of instrumentation, and the underdevelopment of fluorescence lifetime probes with AIE characteristics. A promising solution to these challenges lies in aggregation-induced emission (AIE) fluorophores, which overcome issues such as aggregation-caused quenching and photobleaching. Despite their potential, AIE fluorophores have been rarely integrated with FLIM, leaving a significant gap in bioimaging research. Integrating FLIM with AIE probes could revolutionize bioimaging, enabling precise, stable, and environment-sensitive lifetime imaging for diagnostics, metabolism, and live-cell monitoring. In this perspective, we examine the potential of FLIM-AIE integration in bioimaging, highlighting its advantages, identifying key barriers, and proposing strategies to promote its use in biomedical research. We highlight the critical role of interdisciplinary collaboration, enhanced training programs, and targeted funding initiatives in accelerating innovation in the field of bioimaging.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.